<DOC>
	<DOCNO>NCT00192400</DOCNO>
	<brief_summary>The purpose study determine efficacy liquid formulation CAIV-T culture confirm influenza illness healthy child age least 6 month le 36 month .</brief_summary>
	<brief_title>Trial Assess Safety Tolerability Liquid Formulation CAIV-T Healthy Children .</brief_title>
	<detailed_description />
	<criteria>( First Season ) age least 6 month le 36 month age time enrollment ; good health determine medical history , physical examination clinical judgement ; whose parent ( ) /legal guardian ( ) provide write informed consent nature study explain ; , along parent ( ) /legal guardian ( ) , available completion first season ’ surveillance phase ; whose parent ( ) /legal guardian ( ) , reach study staff postvaccination contact [ telephone , clinic home visit ] . ( Second Season ) enrol first season trial receive least one vaccination primary series ; complete safety efficacy evaluation first season surveillance phase ; good health determine medical history , physical examination clinical judgement ; whose parent ( ) /legal guardian ( ) provide write informed consent second season trial nature study explain ; , along parent ( ) /legal guardian ( ) , available completion second season ’ surveillance phase ; whose parent ( ) /legal guardian ( ) , reach study staff postvaccination contact [ telephone , clinic home visit ] . ( First Season ) whose parent ( ) /legal guardian ( ) perceive unavailable difficult contact evaluation study visit study period ; serious chronic disease ( e.g. , sign cardiac renal failure severe malnutrition ) , include progressive neurological disease ; Down 's syndrome know cytogenetic disorder ; know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid ; receive blood product , include immunoglobulin , period six month prior vaccination conclusion study ; intent administer investigational vaccine agent one month prior enrollment conclusion study ; immunosuppressed immunocompromised individual living household ; , time prior entry study , receive dose influenza vaccine ( commercial investigational ) ; , two week prior entry study , receive dose influenza treatment ( commercial investigational ) ; document history hypersensitivity egg egg protein component assign study vaccine ; clinically confirm respiratory illness wheeze within two week prior enrollment ; receive aspirin ( acetylsalicylic acid ) aspirincontaining product two week prior enrollment use anticipate study ; administer live virus vaccine within one month prior enrollment expect receive another live virus vaccine within one month vaccination study ; medical condition opinion investigator might interfere interpretation study result . If criterion meet follow enrolment , subject exclude subsequent vaccine dosing . Note : Pregnancy household member person regular contact subject contraindication enrollment ongoing participation subject study . ( Second Season ) whose parent ( ) /legal guardian ( ) perceive unavailable difficult contact evaluation study visit study period ; serious chronic disease ( e.g. , sign cardiac renal failure severe malnutrition ) , include progressive neurological disease ; Down 's syndrome know cytogenetic disorder ; know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid dose equivalent 2 mg/kg/day great prednisolone equivalent total 20 mg/day great child weigh 10 kg , 14 day duration 2 week corticosteroid discontinue ; receive blood product , include immunoglobulin , period six month prior second season vaccination conclusion study ; intent administer investigational vaccine agent one month prior second season vaccination conclusion study ; immunosuppressed immunocompromised individual living household ; , time prior entry study , receive dose influenza vaccine ( commercial investigational ) exception primary series study vaccine ( CAIVT/placebo ) ; , two week prior receive second season vaccination , receive dose influenza treatment ( commercial investigational ) ; document history hypersensitivity egg egg protein component assign study vaccine ( CAIVT/placebo ) ; clinically confirm respiratory illness wheeze within two week prior receive second season vaccination ; receive aspirin ( acetylsalicylic acid ) aspirincontaining product two week prior receive second season vaccination use anticipate study ; administer live virus vaccine within one month prior receive second season vaccination expect receive another live virus vaccine within one month receive second season vaccination ; medical condition opinion investigator might interfere interpretation study result . Note : Pregnancy household member person regular contact subject contraindication enrollment ongoing participation subject study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>